News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene Corporation (CELG) Release: Phase II Study Evaluates Clinical Benefit of Pomalidomide in Heavily Pre-Treated Patients with Multiple Myeloma


12/13/2011 7:28:37 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced that its oral therapy pomalidomide was evaluated as a potential treatment for patients with relapsed and refractory multiple myeloma who have received prior therapy that includes REVLIMID (lenalidomide) and bortezomib. The clinical data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES